ADMA Biologics (NASDAQ: ADMA) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare ADMA Biologics to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Risk and Volatility

ADMA Biologics has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, ADMA Biologics’ rivals have a beta of 0.94, indicating that their average share price is 6% less volatile than the S&P 500.

Profitability

This table compares ADMA Biologics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ADMA Biologics -35.00% -76.26% -9.77%
ADMA Biologics Competitors -5,104.97% -168.07% -35.21%

Institutional & Insider Ownership

32.8% of ADMA Biologics shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 60.4% of ADMA Biologics shares are owned by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares ADMA Biologics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ADMA Biologics $10.66 million -$19.51 million -1.61
ADMA Biologics Competitors $284.49 million $34.10 million 64.35

ADMA Biologics’ rivals have higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ADMA Biologics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics 0 0 2 0 3.00
ADMA Biologics Competitors 897 3297 11783 236 2.70

ADMA Biologics presently has a consensus price target of $6.50, suggesting a potential upside of 102.49%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.34%. Given ADMA Biologics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe ADMA Biologics is more favorable than its rivals.

Summary

ADMA Biologics beats its rivals on 8 of the 13 factors compared.

ADMA Biologics Company Profile

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Receive News & Stock Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related stocks with our FREE daily email newsletter.